Progression-free survival curves with BCMA retreatment. (A-C) PFS curves for subsequent BCMA-directed CAR-T (A), BCMA-directed BsAb (B), and belantamab mafadotin (C). (D) OS stratified by the receipt of subsequent BCMA-directed CAR-T or BsAb within 6 months of progression from original CAR-T.